Zacks Investment Research upgraded shares of DBV Technologies S.A. (NASDAQ:DBVT) from a hold rating to a buy rating in a research note released on Thursday morning. Zacks Investment Research currently has $38.00 price objective on the stock.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
A number of other research firms have also recently weighed in on DBVT. Jefferies Group LLC set a $47.00 price target on shares of DBV Technologies and gave the stock a buy rating in a research note on Monday, October 24th. JMP Securities initiated coverage on shares of DBV Technologies in a research note on Monday, September 26th. They issued an outperform rating and a $47.00 price objective on the stock. Six analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and a consensus target price of $45.80.
Shares of DBV Technologies (NASDAQ:DBVT) opened at 34.79 on Thursday. DBV Technologies has a 12 month low of $22.55 and a 12 month high of $37.98. The firm’s 50 day moving average is $35.28 and its 200-day moving average is $35.33. The firm’s market capitalization is $1.60 billion.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tocqueville Asset Management L.P. raised its position in DBV Technologies by 22.0% in the second quarter. Tocqueville Asset Management L.P. now owns 25,000 shares of the company’s stock worth $816,000 after buying an additional 4,500 shares during the period. JPMorgan Chase & Co. raised its position in shares of DBV Technologies by 6.6% in the second quarter. JPMorgan Chase & Co. now owns 254,492 shares of the company’s stock valued at $8,301,000 after buying an additional 15,849 shares during the last quarter. TimesSquare Capital Management LLC raised its position in shares of DBV Technologies by 0.6% in the third quarter. TimesSquare Capital Management LLC now owns 990,503 shares of the company’s stock valued at $35,985,000 after buying an additional 5,950 shares during the last quarter. Exane Asset Management bought a new position in shares of DBV Technologies during the second quarter valued at $4,407,000. Finally, TD Asset Management Inc. bought a new position in shares of DBV Technologies during the third quarter valued at $272,000. Institutional investors own 48.98% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Get a free copy of the Zacks research report on DBV Technologies (DBVT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com